Fenwick Represents TrexBio in $84M Series B Financing

Fenwick represented TrexBio, a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, in its $84 million Series B financing. The round was led by Delos Capital, with participation from Avego BioScience Capital, Agent Capital, Eli Lilly and Company, SV Health Investors, Pfizer Ventures, Johnson & Johnson, Alexandria Venture Investments, and Polaris Partners.

TrexBio will use the funds to advance their lead candidate, TRB-061, a purpose-engineered TNFR2 agonist, through early clinical proof of concept in patients with immune mediated diseases including atopic dermatitis and ulcerative colitis. More information can be obtained from the company announcement.

The Fenwick transaction team was led by corporate partners Effie Toshav and Jonathan Sagot and included associates Warren Hill, Kosha Patel, and Michael Murrieta.